Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks

Abstract

Advanced therapies (biologic agents and small molecules) for inflammatory bowel diseases (IBD) have radically changed the management of these diseases during the last decade. Data about these drugs in patients with hepatic disorders derive mainly from real-life studies, as these conditions often represent an exclusion criterion from pivotal drug developmental trials. However, IBD patients sometimes have concomitant liver diseases. Nonalcoholic fatty liver disease is the most prevalent hepatic comorbidity, whereas viral hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, and hepatic vascular disorders are less frequent. This review aimed at describing the real-life data about the use of advanced therapies for IBD in patients with concomitant hepatobiliary disorders. Hepatitis B virus and hepatitis C virus infections do not represent an absolute contraindication for novel IBD therapeutic agents. Data from the literature suggest a safe hepatobiliary profile of biologic agents and small molecules in the case of nonalcoholic fatty liver disease, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, and portal vein thrombosis. Consequently, although the liver disease does not affect a different therapeutic approach in patients with concomitant IBD and liver disease, a close risk/benefit analysis for each drug should be performed in these patients, especially in cirrhotic patients and in the postliver transplant setting.

Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances

“…IBD is a chronic and complex condition that causes inflammation in the gastrointestinal tract, leading to conditions such as ulcerative colitis (UC) and Crohn's disease (CD). 1 In North America and Europe, more than 1.5 million and 2 million people, respectively, have been diagnosed with IBD since the turn of the century. The incidence of IBD is also rapidly increasing in Asia, including in China, India, and other underdeveloped regions.…”

Picroside III Ameliorates Colitis in Mice: A Study Based on Colon Transcriptome and Fecal 16S Amplicon Profiling

“…Inflammatory Bowel Disease (IBD) is a prevalent, chronic immunological disorder characterized by impaired intestinal function, manifesting in symptoms such as diarrhea, rectal bleeding, abdominal pain, and weight loss [1,2] . Epidemiological studies have highlighted a high incidence of IBD in Western countries.…”